Localized incompletely resected standard risk rhabdomyosarcoma in children and adolescents: Results from the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 trial

IF 5.1 2区 医学 Q1 ONCOLOGY Cancer Pub Date : 2024-07-26 DOI:10.1002/cncr.35497
Henry C. Mandeville MBChB, MD(Res), Gianni Bisogno MD, PhD, Veronique Minard-Colin MD, PhD, Rita Alaggio MD, Myriam Ben-Arush MD, Cyrus Chargari MD, PhD, Beatrice Coppadoro BSc, Ross Craigie MBChB, Christine Devalck MD, Sima Ferman MD, PhD, Andrea Ferrari MD, Heidi Glosli MD, Raquel Hladun Alvaro MD, Marinka Hol MD, PhD, Peter Mudry MD, Daniel Orbach MD, Monica Ramos Albiac MD, Johannes H. M. Merks MD, PhD, Meriel E. M. Jenney MBChB, MD
{"title":"Localized incompletely resected standard risk rhabdomyosarcoma in children and adolescents: Results from the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 trial","authors":"Henry C. Mandeville MBChB, MD(Res),&nbsp;Gianni Bisogno MD, PhD,&nbsp;Veronique Minard-Colin MD, PhD,&nbsp;Rita Alaggio MD,&nbsp;Myriam Ben-Arush MD,&nbsp;Cyrus Chargari MD, PhD,&nbsp;Beatrice Coppadoro BSc,&nbsp;Ross Craigie MBChB,&nbsp;Christine Devalck MD,&nbsp;Sima Ferman MD, PhD,&nbsp;Andrea Ferrari MD,&nbsp;Heidi Glosli MD,&nbsp;Raquel Hladun Alvaro MD,&nbsp;Marinka Hol MD, PhD,&nbsp;Peter Mudry MD,&nbsp;Daniel Orbach MD,&nbsp;Monica Ramos Albiac MD,&nbsp;Johannes H. M. Merks MD, PhD,&nbsp;Meriel E. M. Jenney MBChB, MD","doi":"10.1002/cncr.35497","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The authors report the prospective evaluation of reduced dose alkylator chemotherapy combined with radiotherapy for European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) standard risk nonalveolar rhabdomyosarcoma (NA-RMS).</p>\n </section>\n \n <section>\n \n <h3> Patients and Methods</h3>\n \n <p>Localized node negative Intergroup Rhabdomyosarcoma Study (IRS) II/III NA-RMS at favorable sites (subgroup C), &lt;25 years old, received five cycles of ifosfamide, vincristine, and dactinomycin (IVA) chemotherapy (30 g/m<sup>2</sup> ifosfamide) and four cycles of vincristine and dactinomycin (if receiving radiotherapy), or nine cycles of IVA (54 g/m<sup>2</sup> ifosfamide) ± radiotherapy. Delayed primary tumor excision was considered for IRS III tumors. The primary end points were event-free survival (EFS) and overall survival (OS).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>From October 2005 to December 2016, 359 evaluable patients were recruited: orbit, 164 (45.7%); head and neck nonparameningeal, 77 (21.4%); and genitourinary non–bladder/prostate, 118 (32.9%). EFS and OS were 77.4% (95% confidence interval [CI], 72.5–81.6) and 93.5% (95% CI, 90.1–95.8), respectively. Lower dose alkylator chemotherapy and radiotherapy achieved 5-year OS of 93.7% but the difference with higher dose alkylator chemotherapy +/- radiotherapy was not significant (<i>p</i> = 0.8003). Adjuvant radiotherapy improved EFS with 5-year estimates of 84.7% versus 65.2% for nonirradiated (<i>p</i> &lt; .0001), but not OS (<i>p</i> = .9298). Omitting radiotherapy for orbital tumors reduced OS (5-year was 87.1% vs. 97.3% for irradiated, <i>p</i> = .0257). Following R0 resection (<i>n</i> = 60), radiotherapy did not significantly improve EFS or OS.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Radiotherapy for local tumor control allows for reduction of cumulative dose of alkylators in EpSSG standard risk subgroup C RMS patients. The omission of radiotherapy did not affect OS in all patients except those with orbital RMS and was associated with inferior EFS.</p>\n </section>\n </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"130 23","pages":"4071-4084"},"PeriodicalIF":5.1000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35497","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer","FirstCategoryId":"3","ListUrlMain":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35497","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The authors report the prospective evaluation of reduced dose alkylator chemotherapy combined with radiotherapy for European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) standard risk nonalveolar rhabdomyosarcoma (NA-RMS).

Patients and Methods

Localized node negative Intergroup Rhabdomyosarcoma Study (IRS) II/III NA-RMS at favorable sites (subgroup C), <25 years old, received five cycles of ifosfamide, vincristine, and dactinomycin (IVA) chemotherapy (30 g/m2 ifosfamide) and four cycles of vincristine and dactinomycin (if receiving radiotherapy), or nine cycles of IVA (54 g/m2 ifosfamide) ± radiotherapy. Delayed primary tumor excision was considered for IRS III tumors. The primary end points were event-free survival (EFS) and overall survival (OS).

Results

From October 2005 to December 2016, 359 evaluable patients were recruited: orbit, 164 (45.7%); head and neck nonparameningeal, 77 (21.4%); and genitourinary non–bladder/prostate, 118 (32.9%). EFS and OS were 77.4% (95% confidence interval [CI], 72.5–81.6) and 93.5% (95% CI, 90.1–95.8), respectively. Lower dose alkylator chemotherapy and radiotherapy achieved 5-year OS of 93.7% but the difference with higher dose alkylator chemotherapy +/- radiotherapy was not significant (p = 0.8003). Adjuvant radiotherapy improved EFS with 5-year estimates of 84.7% versus 65.2% for nonirradiated (p < .0001), but not OS (p = .9298). Omitting radiotherapy for orbital tumors reduced OS (5-year was 87.1% vs. 97.3% for irradiated, p = .0257). Following R0 resection (n = 60), radiotherapy did not significantly improve EFS or OS.

Conclusions

Radiotherapy for local tumor control allows for reduction of cumulative dose of alkylators in EpSSG standard risk subgroup C RMS patients. The omission of radiotherapy did not affect OS in all patients except those with orbital RMS and was associated with inferior EFS.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
儿童和青少年局部未完全切除的标准风险横纹肌肉瘤:欧洲儿童软组织肉瘤研究小组 RMS 2005 试验结果。
研究背景作者报告了对欧洲小儿软组织肉瘤研究组(EpSSG)标准风险非肺泡横纹肌肉瘤(NA-RMS)减量烷化剂化疗联合放疗的前瞻性评估:在有利部位(C亚组)进行局部结节阴性的Intergroup Rhabdomyosarcoma Study(IRS)II/III NA-RMS,2次ifosfamide)和4个周期的长春新碱和双霉素(如果接受放疗),或9个周期的IVA(54克/平方米ifosfamide)±放疗。对于IRS III肿瘤,考虑延迟原发肿瘤切除术。主要终点为无事件生存期(EFS)和总生存期(OS):2005年10月至2016年12月,共招募了359例可评估患者:其中眼眶肿瘤164例(45.7%);头颈部非副脑膜肿瘤77例(21.4%);泌尿生殖系统非膀胱/前列腺肿瘤118例(32.9%)。EFS 和 OS 分别为 77.4%(95% 置信区间 [CI],72.5-81.6)和 93.5%(95% 置信区间 [CI],90.1-95.8)。低剂量烷化剂化疗和放疗的5年生存率为93.7%,但与高剂量烷化剂化疗+/-放疗相比,差异不显著(P = 0.8003)。辅助放疗改善了患者的生存期,5 年生存率估计为 84.7%,而未接受放疗的患者为 65.2%(p 结论:辅助放疗改善了患者的生存期,5 年生存率估计为 84.7%,而未接受放疗的患者为 65.2%:在EpSSG标准风险C亚组RMS患者中,局部肿瘤控制放疗可减少烷化剂的累积剂量。除眼眶RMS患者外,不进行放疗不会影响所有患者的OS,但与较差的EFS有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer
Cancer 医学-肿瘤学
CiteScore
13.10
自引率
3.20%
发文量
480
审稿时长
2-3 weeks
期刊介绍: The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society. CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research
期刊最新文献
Correction to "The effect of common medications on the efficacy of immune checkpoint inhibitors". Comments on chemoradiotherapy in IDH wild-type/TERT-mutant grade 2/3 gliomas. Assessing patient perspectives on enrollment in lymphoma clinical trials. Health care discrimination and self-reported health in transgender, gender nonconforming, and nonbinary individuals with cancer. Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1